Silexion Therapeutics Corp: Clinical-Stage KRAS Oncology Innovations and siRNA Pipeline for Pancreatic Cancer

Silexion Therapeutics Corp 2025 Annual Report: Key Highlights for Investors

Overview

Silexion Therapeutics Corp (“Silexion” or the “Company”), a Cayman Islands-based biopharmaceutical company, has released its Annual Report for the fiscal year ended December 31, 2025. The Company, focused on developing novel RNAi therapeutics for oncology, trades on The Nasdaq Stock Market LLC under the symbol SLXN, with warrants trading as SLXNW.

Key Points and Potential Share Price Movers

1. Development-Stage Company with Limited Operating History

Silexion is a development-stage company with a limited operating history. The Company’s core technology—RNAi therapeutics for oncology—is an unproven approach and may never lead to marketable products.
No revenue has been generated from product sales to date, and profitability is not anticipated in the near future.

2. Financial Position and Going Concern Risks

The Company’s independent registered public accounting firm has issued a “going concern” warning, expressing substantial doubt about Silexion’s ability to continue operations without additional funding.
Silexion will require significant additional capital to fund operations and clinical development, including for its lead candidate, SIL204. Funding may be sourced from public offerings, private placements, warrant exercises, or alternative financings.
The Company has an At The Market (ATM) Offering Agreement with H.C. Wainwright, allowing for the sale of up to \$13,170,000 in ordinary shares. This could result in substantial dilution to existing shareholders.
The Company can convert the remaining principal balance of a \$3,433,000 A&R Sponsor Promissory Note without shareholder approval, which could also cause dilution and downward pressure on the share price.

3. Corporate Actions Impacting Share Structure

In the past year, Silexion effected two significant reverse share splits: a 1-for-9 split in November 2024 and a 1-for-15 split in July 2025. All historical share information has been retroactively adjusted.
The Company warns that it may need to effect additional reverse splits, which could cause “extreme price volatility” in the aftermath.

4. Nasdaq Listing and Compliance Risks

Silexion’s securities are currently listed on Nasdaq. Failure to maintain compliance with Nasdaq’s continued listing requirements could result in delisting, which would significantly impact share liquidity and value.
The Company is classified as a “non-accelerated filer,” a “smaller reporting company,” and an “emerging growth company,” which may impact its reporting and compliance obligations.

5. Geopolitical and Operational Risks

Silexion operates primarily through its Israeli subsidiary. The Company highlights that “conditions in the Middle East and in Israel may harm our operations,” which introduces significant geopolitical risk.

6. No Plans for Cash Dividends

The Company has no current plans to pay cash dividends on its ordinary shares for the foreseeable future.

7. Warrants and Potential Dilution

Silexion has outstanding warrants exercisable for ordinary shares at an exercise price of \$1,552.50 per share. Exercise of these warrants, as well as shares issued under the ATM, could cause substantial dilution.
The Company can issue a “substantial number” of new shares under the ATM and/or conversion of the Sponsor Promissory Note, both of which could put significant downward pressure on the share price.

Summary of Risks for Shareholders

Unproven technology in oncology; no product revenue; high risk of failure.
Substantial additional capital needed; high likelihood of dilution and share price decreases.
Going concern warning from auditors; risk of business cessation if capital is not raised.
Recent and potential future reverse splits; history of extreme price volatility.
Possible Nasdaq delisting if listing requirements are not met.
Operations exposed to geopolitical instability in Israel and the Middle East.
No dividends; all retained earnings reinvested or used for operations.

Additional Information

No error corrections or restatements required during the reporting period.
No documents incorporated by reference; this report contains the full disclosure.

Conclusion

Investors should be aware that Silexion Therapeutics Corp presents a high-risk, high-volatility investment profile. The need for substantial additional funding, history of reverse splits, and dilution risk from both the ATM facility and the Sponsor Promissory Note are critical factors. Moreover, operational risks in Israel and the unproven nature of its RNAi oncology pipeline add further uncertainty. These factors could significantly impact the Company’s share price in both positive and negative directions depending on developments.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisor before making investment decisions. The information is based on Silexion Therapeutics Corp’s 2025 Annual Report as filed with the SEC and may be subject to change or correction. The Company operates in a high-risk sector and its shares may be highly volatile.